›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:TheraSure™-CNI MONITOR Assay
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
OncocyteType:
Laboratory Developed Test
Related tests:
The Chronix CNI test is a patented, novel blood-based test that is differentiated from current methods because it requires no upfront tumor tissue sample. This liquid biopsy diagnostic uses copy number instability (CNI) to sensitively quantify the cell-free DNA from the primary solid tumor in a patient’s blood.
Cancer:
Solid Tumor
Gene:
ARID1A (AT-rich interaction domain 1A), ATM (ATM serine/threonine kinase), BIRC3 (Baculoviral IAP repeat containing 3), BRCA1 (Breast cancer 1, early onset), CDKN2C (Cyclin Dependent Kinase Inhibitor 2C), EGFR (Epidermal growth factor receptor)
See More ...
ARID1A (AT-rich interaction domain 1A), ATM (ATM serine/threonine kinase), BIRC3 (Baculoviral IAP repeat containing 3), BRCA1 (Breast cancer 1, early onset), CDKN2C (Cyclin Dependent Kinase Inhibitor 2C), EGFR (Epidermal growth factor receptor), FANCD2 (FA Complementation Group D2), FBXO11 (F-Box Protein 11), FBXW7 (F-Box And WD Repeat Domain Containing 7), MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4), MDM4 (The mouse double minute 4), MLH1 (MutL homolog 1), NF1 (Neurofibromin 1), NF2 (Neurofibromin 2), PBRM1 (Polybromo 1), SMAD4 (SMAD family member 4), SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1), SOX2, WT1 (WT1 Transcription Factor)
